In this talk, Dr. Frank Peacock shares how newly available diagnostic testing can significantly alter the early therapy of sepsis and thus potentially save lives. Early objective results allow faster accurate targeted therapy, thus providing the potential to improve patient outcomes and lower hospital costs. Dr. Peacock presents on the T2Bacteria and T2Candida Panels, the first FDA-cleared tests to directly provide early species-specific results for sepsis-causing pathogens, in 3 to 5 hours after a blood draw.
W. Frank Peacock IV, MD, FACEP, FACC is a Professor of Emergency Medicine, Associate Chair, and Research Director for the department of Emergency Medicine at the Baylor College of Medicine, in Houston, Texas. He serves as a member of the Accreditation Management Board for the American College of Cardiology, as well as on the NCDR Action Registry-Get With The Guidelines Research and Publications Subcommittee.